Golden State Equity Partners Purchases Shares of 2,288 Eli Lilly and Company (NYSE:LLY)

Golden State Equity Partners acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,288 shares of the company’s stock, valued at approximately $786,000.

Other hedge funds have also bought and sold shares of the company. Silicon Valley Capital Partners bought a new position in Eli Lilly and Company during the first quarter worth $25,000. Bogart Wealth LLC lifted its stake in shares of Eli Lilly and Company by 193.3% during the 1st quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock worth $30,000 after buying an additional 58 shares during the last quarter. Laffer Tengler Investments bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $33,000. Raleigh Capital Management Inc. grew its stake in Eli Lilly and Company by 156.4% in the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock valued at $34,000 after buying an additional 61 shares during the last quarter. Finally, Tanglewood Legacy Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at about $37,000. 81.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $500.00 to $615.00 and gave the stock an “overweight” rating in a report on Tuesday, August 8th. UBS Group boosted their price target on Eli Lilly and Company from $447.00 to $498.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. Royal Bank of Canada increased their price objective on Eli Lilly and Company from $490.00 to $580.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. BMO Capital Markets boosted their target price on shares of Eli Lilly and Company from $565.00 to $633.00 and gave the company an “outperform” rating in a research report on Wednesday, August 9th. Finally, Truist Financial raised their price target on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $532.78.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $571.41, for a total transaction of $119,996,100.00. Following the completion of the sale, the insider now directly owns 99,983,810 shares in the company, valued at $57,131,748,872.10. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the sale, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $571.41, for a total value of $119,996,100.00. Following the sale, the insider now directly owns 99,983,810 shares of the company’s stock, valued at approximately $57,131,748,872.10. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,036,514 shares of company stock worth $21,107,445,590. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Down 0.8 %

Shares of LLY stock traded down $4.78 during trading hours on Wednesday, hitting $594.52. 1,617,093 shares of the company’s stock traded hands, compared to its average volume of 3,012,498. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. Eli Lilly and Company has a 12 month low of $296.32 and a 12 month high of $601.13. The stock has a market cap of $564.37 billion, a PE ratio of 82.69, a price-to-earnings-growth ratio of 2.36 and a beta of 0.32. The stock’s 50 day simple moving average is $504.85 and its 200 day simple moving average is $433.48.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, August 8th. The company reported $2.11 EPS for the quarter, topping the consensus estimate of $1.98 by $0.13. The firm had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.25 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 9.83 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.76%. Eli Lilly and Company’s payout ratio is 62.87%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.